CJC-1295 (without DAC) and Telmisartan Interaction

Synergistic
Mechanism-based 51% confidence

CJC-1295 (without DAC) and Telmisartan have a synergistic interaction with 51% confidence. CJC-1295 (without DAC) helps counteract the insulin-disrupting effects of Telmisartan. A smart combination — the insulin sensitizer mitigates metabolic side effects. These compounds primarily affect different organ systems.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss
ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

Telmisartan

Angiotensin II Receptor Blocker | Cardiac Protection On Cycle

Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling.

Half-life: ~24 hours Typical dose: 20-80 mg/day cardiovascular
ppar gamma blood pressure raisinghepatotoxicinsulin sensitizingteratogenic
View full profile

Combined Organ Load

GI Tract
low
Pituitary
low
Heart
low

Shared Safety Flags

2x 2 compounds share the teratogenic safety flag (CJC-1295 (without DAC), Telmisartan). Monitor accordingly.

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with Telmisartan?

Yes, CJC-1295 (without DAC) and Telmisartan can generally be taken together. CJC-1295 (without DAC) helps counteract the insulin-disrupting effects of Telmisartan. A smart combination — the insulin sensitizer mitigates metabolic side effects.

Is CJC-1295 (without DAC) and Telmisartan safe together?

Based on pharmacological analysis, this combination is considered synergistic. However, shared safety flags include: teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and Telmisartan?

CJC-1295 (without DAC) helps counteract the insulin-disrupting effects of Telmisartan. A smart combination — the insulin sensitizer mitigates metabolic side effects. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 (without DAC) and Telmisartan?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and Telmisartan has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 (without DAC) vs Telmisartan

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.